Salute e Benessere
IBS and IBD Treatment Market to Show Strong Growth | BCC Research LLC
The report provides a detailed analysis of the global market for therapeutics targeting irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). It segments the market by disease type, symptom type, and drug class. IBS therapeutics are categorized into IBS with constipation, diarrhea, and mixed symptoms, with treatments including guanylate cyclase-C agonists, antibiotics, laxatives, and antispasmodics. IBD therapeutics are divided into ulcerative colitis and Crohn's disease, with drug classes such as interleukin inhibitors, integrin antagonists, TNF inhibitors, and JAK inhibitors. The report also analyzes the regional markets of North America , Europe , Asia-Pacific , South America , and the Middle East and Africa , and includes a discussion of the competitive landscape and company profiles.
This report is particularly relevant today due to the increasing global burden of gastrointestinal conditions like IBS and IBD, which are especially common in the U.S. and Europe . These chronic diseases significantly affect patients' quality of life. The growing number of diagnoses across all age groups, including children and the elderly, is fueling demand for more effective treatments. Additionally, the surge in product approvals and the introduction of biosimilars for IBD are intensifying market competition.
Biologics offer targeted treatment for severe cases of IBD, while biosimilars provide more affordable alternatives. Their development is expanding access to advanced therapies and fueling market growth.
Patients increasingly prefer treatments that can be taken at home, such as oral medications or injectable drugs. This trend enhances convenience and adherence, encouraging pharmaceutical companies to innovate in drug delivery.
Advances in genetics and biomarkers are enabling customized treatments tailored to individual patient profiles. Personalized therapies improve outcomes and reduce side effects, making them a focus in modern gastrointestinal care.
• Rising prevalence of self-administered drugs.
• Increasing availability of personalized therapies.
For further information on any of these reports or to make a purchase, contact info@bccresearch.com.
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype.
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.
Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.
Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ibs-and-ibd-treatment-market-to-show-strong-growth--bcc-research-llc-302527770.html